IPR decision: Sep 27, 2019
|
AIA Review #
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent
|
Respondent
|
Status
|
|
IPR2016-01127
|
06/03/2016
|
12/08/2016
|
Mylan
|
8685930
|
Allergan, Inc.
|
Terminated-Dismissed
|
|
IPR2016-01128
|
06/03/2016
|
12/08/2016
|
Mylan
|
8629111
|
Allergan, Inc.
|
Terminated-Dismissed
|
|
IPR2016-01129
|
06/03/2016
|
12/08/2016
|
Mylan
|
8642556
|
Allergan, Inc.
|
Claims are unpatentable
|
|
IPR2016-01130
|
06/03/2016
|
12/08/2016
|
Mylan
|
8633162
|
Allergan, Inc.
|
Claims are unpatentable
|
|
IPR2016-01131
|
06/03/2016
|
12/08/2016
|
Mylan
|
8648048
|
Allergan, Inc.
|
Terminated-Dismissed
|
|
IPR2016-01132
|
06/03/2016
|
12/08/2016
|
Mylan
|
9248191
|
Allergan, Inc.
|
Terminated-Dismissed
|
On US’930 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, terminated & instituted respectively.
On US’111 patent, Apotex, Argentum, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, terminated, terminated & instituted respectively.
On US’556 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, terminated & instituted respectively.
On US’162 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, instituted & terminated respectively.
On US’048 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, instituted & terminated respectively.
On US’191 patent, Famy Care, Teva & Akorn filed IPR petitions which were terminated, instituted & terminated respectively.
US 8,685,930 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a topical ophthalmic emulsion for treating an eye of a human having keratoconjunctivitis sicca, dry eye & or increasing tear production.
US 8,629,111 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a topical ophthalmic emulsion for treating an eye comprising cyclosporin A with certain excipients.
US 8,642,556 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a first topical ophthalmic emulsion for treating an eye comprising cyclosporin A with certain excipients.
US 8,633,162 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a method of treating dry eye disease comprising cyclosporin A with certain excipients.
US 8,648,048 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a method of increasing tear production in the eye comprising cyclosporin A with certain excipients.
US 9,248,191 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a method of treating dry eye disease comprising cyclosporin A with certain excipients.
Leave a Reply